Wild-type status of KRAS and the NRAS gene (exon 2, 3, and 4) in the tumor should be determined before treatment of metastatic colorectal cancer (mCRC) patients with EGFR-targeting agents. There is a large variation in test methods to determine RAS status, and more sensitive detection methods were recently introduced. Data from quality assessment programs indicate substantial error rates. This study assessed the completeness and correctness of RAS testing in European laboratories that successfully passed external quality assessment (EQA). Participants were requested to send material of their most recent ten patients with mCRC who had been tested for RAS status. Isolated DNA, a hematoxylin and eosin stained tissue slide with a marked area for macrodissection and accompanying patient reports were requested. Samples were reevaluated in a reference laboratory by using a next-generation sequencing approach. In total, 31 laboratories sent in the requested material (n = 309). Despite regulations for anti-EGFR therapy, one institute did not perform full RAS testing. Reanalysis was possible for 274 samples with sufficient DNA available. In the hotspot codons of KRAS and NRAS, seven discordant results were obtained in total, five of them leading to a different prediction of anti-EGFR therapy efficacy (2%; n = 274). Results show that oncologists can rely on the quality of laboratories with good performance in EQA. Oncologists need to be aware that the testing laboratory participates successfully in EQA programs. Some EQA providers list the good performing laboratories on their website.
Introduction
Today, variants in the KRAS and the NRAS genes (exon 2, 3, and 4) are considered to be important biomarkers for anti-EGFR therapy decisions for patients with metastatic colorectal cancer (mCRC). Targeted anti-EGFR agents, such as panitumumab and cetuximab, are indicated only for patients with a wild-type RAS tumor [1, 2] . Pathology laboratories perform KRAS variant analysis since 2008, when it became mandatory to confirm the wild-type status of KRAS exon 2 before anti-EGFR treatment is prescribed [3] . The outcome of phase III trials (PRIME and FIRE) in 2013 resulted in addition of the mutational status of NRAS and extra exons of KRAS as predictive biomarkers for anti-EGFR therapy decisions [4] .
Another important biomarker is a somatic activating variant affecting the BRAF gene. This is a well-known negative prognostic marker in mCRC, but testing is not mandatory prior to anti-EGFR therapy decisions. Even though many laboratories include BRAF in their testing strategy for anti-EGFR This article is part of the Topical Collection on Quality in Pathology Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00428-017-2291-z) contains supplementary material, which is available to authorized users. therapy, there is no consensus about the specific effect of activating variants in BRAF on this therapy [5, 6] .
Shortly after publication of the more stringent rules for panitumumab and cetuximab usage, results of external quality assessments (EQAs) showed concerning results [7] [8] [9] . Full RAS testing (defined as codons 12, 13, 59, 61, 117, and 146 of KRAS and NRAS) was only implemented by half of the laboratories participating in the European Society of Pathology (ESP) program, and there were numerous errors in testing the new gene segments. False positive and false negative results can have detrimental consequences for the patient's treatment and must be avoided at all times [10] .
There is a large variation in the testing methods used to determine the RAS and BRAF status and more sensitive detection methods were introduced in routine testing [11] . There is a risk of reporting false negative or false positive results due to different sensitivities of methods, lack of experience in the laboratory, and other, partly unknown, factors. In the Netherlands, where few laboratories fail EQA programs, the result of retesting routine samples was reassuring [12] .
In this study, the completeness and correctness of RAS testing (KRAS and NRAS exons 2, 3, and 4) was assessed in a subset of European laboratories, from 17 different countries, that successfully participated in previous EQA schemes.
Materials and methods
All European laboratories that were successful in at least one of their two last ESP Colon EQA scheme participations [13] , with a known accreditation status that did not change in the last 3 years, were invited to participate in this study (n = 126). From 50 candidature forms, a final selection of 42 laboratories was made depending on the most recent participation in the ESP Colon EQA scheme.
Participating laboratories were requested the following material of the most recent ten patients tested for RAS variant status (January-September 2016): a hematoxylin and eosin (H&E) slide marked with the area used for macrodissection and DNA isolation, 50 μl DNA (10 ng/μl) to accommodate automatic processing in the reference laboratory, and the original test reports. The participants received a survey regarding the testing strategy and the techniques used to analyze the samples.
The DNA samples received from the participating laboratories were retested in the Department of Pathology at Radboudumc, Nijmegen, the Netherlands. This laboratory is accredited according to ISO 15189 for their NGS activities and will be further referred to as Bthe reference laboratory^. The anonymized original reports were received and analyzed in the Biomedical Quality Assurance Research Unit of the KU Leuven (Belgium). Any discordant result between the participant's result and the reference laboratory was repeated in the reference laboratory.
The histological slides were reviewed individually for neoplastic cell percentage by two pathologists who used a recently developed algorithm, which was finalized by a consensus to a single value. Quantification of the DNA in the samples was done using the dsDNA broad range kit on the Qubit 3.0 platform (Thermo Fisher Scientific). DNA samples with a measurable amount of DNA (n = 294) were analyzed in duplicate using a Cancer Hotspot panel based on single-molecule molecular inversion probes (smMIPs) [14] . For variant calling a threshold of 11 unique reads and 3 variant reads was applied. Due to the high level of formalin-fixed paraffin-embedded artifacts in some samples, the cutoff for the variant allele frequency was set at ≥ 5%. This data analysis was slightly different from the routine strategy, where a cutoff of 1% is used. The mean amount of unique reads varied between 530 (KRAS codon 61) and 1553 (BRAF codon 594-601) (for details, see Supplementary Table 2 ). The data of any discrepant result were reanalyzed in detail, according to the routine procedures. The evaluation was blinded for original test results.
Results from the reference laboratory were compared with results in the original patient reports of the participating laboratories. Information such as sensitivity and neoplastic cell percentage were also available from these reports.
Statistical analysis was done with IBM SPSS statistics version 22. Comparison of means was done with a t test.
Results
From the 42 selected laboratories for this study, 31 laboratories sent in their DNA samples along with respective patient reports. One laboratory did not fill in the requested survey, and for one laboratory, only nine samples were received. A total of 309 samples were received, of which 274 gave reliable results after reanalysis by the reference laboratory. The participants belonged to 17 different countries. More detailed information on the countries and characteristics can be found in Table 1 . The majority of the participants (61%) had a university (hospital) and research background, 36% was a laboratory in a public or a private hospital, and 3% were private laboratories. Only 61% of the institutes was accredited according to an international standard (ISO 15189) or a national equivalent [15] [16] [17] .
The neoplastic cell percentage on the HE slides was reassessed by two pathologists for 270 samples of which the H&E slides were available and ranged between 10 and 90% after consensus. The majority of the samples had an estimation between 30 and 70%. The percentage of neoplastic cells was assessed in total by three different pathologists, two from the reference laboratory and one from the participating laboratory. Paired statistical analysis of these assessments, excluding cases where a range is given instead of an exact percentage of neoplastic cells, showed no significant differences between the original estimate and the consensus estimate in the reference laboratory (p = 0.817, n = 195). Analyses on the neoplastic cell content were performed using the pathology estimations of the reference laboratory. Even though confirmation of the wild-type status of NRAS and KRAS (codons 12, 13, 59, 61, 117, 146) is mandatory before anti-EGFR therapy, one institute did not perform full RAS testing. They did not include codon 59 of the KRAS gene. The majority of the laboratories (84%, n = 31) performed BRAF variant analysis for one or more of the samples. However, 13 of these 26 participants did not perform BRAF testing on all the samples. For one laboratory, none of the BRAF-tested samples could be reanalyzed by the reference laboratory and these were therefore not taken into account for further analysis.
The use of NGS-based methods and non-NGS commercial kits is similar for variant analysis of the KRAS gene, 38% and 39%, respectively. For NRAS and BRAF variant analysis, NGS (42% and 55% respectively) is more popular than commercial non-NGS kits (34 and 19%, respectively). Laboratorydeveloped tests (non-NGS) were used by a quarter of the participants for KRAS, NRAS, and BRAF variant analysis (20%, 23%, and 26%, respectively). One laboratory (3%) used a combination of a commercial non-NGS kit with Sanger sequencing for KRAS variant analysis.
The concordance between the genotype reported by the participating and reference laboratories is presented in Table 2 . Taken into account the tested regions and the samples for which the reanalysis by the reference laboratory gave reliable results, 24 laboratories (77%) were able to correctly type all samples. Of these, four laboratories sent in samples that contained a BRAF variant that was identified by the reference laboratory, but was not included in the tested region of that particular laboratory.
There were seven discordant genotypes at clinically relevant positions: four false negatives, one false positive, one insertion-deletion instead of a single nucleotide substitution, and one sample with a second KRAS mutation. Not more than one genotyping error was made by each laboratory. Table 3 gives a more detailed information on these variants, which all involved a KRAS variant. One of the variants that was missed was due to the limit of detection of the laboratory's method, which was 10% while the missed variant was present at a frequency of 6%. The percentage of tumor cells in this sample was 70%. All seven laboratories with genotyping errors had a university (hospital) and research background and four of them were accredited. The average neoplastic cell content of these seven mistyped samples was 47%, with five of the seven samples above 40%. The percentage of neoplastic cells was known for 233 of the 267 concordant samples. The average neoplastic cell content of the samples that were correctly typed was 52%. The two groups, samples with discordant results and those without do not significantly differ from each other regarding neoplastic cell content (p = 0.535). In total six BRAF p.(V600E) variants and two variants in codon 594 of BRAF were missed by the participants as they were not included in their test regimen. Moreover, seven variants at positions without known clinical relevance were identified (Table 2) .
In Table 4 , an overview is shown for the frequency of the variants in each relevant codon of KRAS, NRAS, and BRAF as determined in the reference laboratory (n = 274). Details on all specific variants can be found in Supplemental Table 1 .
Discussion
The aim of this study was to assess quality of routine RAS testing in Europe, by verifying its reproducibility. In addition, implementation of complete KRAS and NRAS (exons 2, 3, and 4) testing in diagnostic setting was evaluated.
Overall, a very good concordance was observed between the participating laboratories and the reference laboratory (97%). For five patients (2%), the reference laboratory generated a genotype that leads to a different anti-EGFR therapy advice. In two patients (1%), the anti-EGFR therapy advice remained the same. In case the four patients with a false negative result actually received anti-EGFR therapy, this could have had adverse effects instead of improvement of progression-free survival [4] . The participants with discordant results all used different methods (Table 3) . Laboratories using NGS technologies made no mistakes which lead to false negative or false positive results for therapy decisions. This observation may be due to the higher familiarity with genotyping technologies.
A limitation of our study is that not all laboratories had sufficient residual DNA that could be evaluated in the automatic workflow of the reference laboratory. This may have caused a selection bias towards samples with large tumor areas and laboratories that isolated a surplus of DNA in their routine workflow. Actually, six participants indicated that the requested DNA amount was higher than what was extracted in their routine practice. This did not seem to cause much problems, as only for eight samples of these participants the repeat NGS analysis gave low coverage. On the other hand, the amount of DNA supplied by some of the participating laboratories was so low that the concentration could not be measured by Qubit analysis.
The frequency of the variants in the mCRC samples used in this study (Table 4 and Supplemental Table 1 ) is in accordance with previously reported results [4, 12, [18] [19] [20] . KRAS exon 2 variants were most commonly identified (41%) and no NRAS exon 4 variants occurred. BRAF variants were present in 10% of the samples, of which BRAF c.1799T>A p.(Val600Glu) In both samples, this concerned a variant of BRAF codon 594 that causes inactivation rather than activation of BRAF. In contrast to BRAF codon 600 variants, which are considered mutually exclusive with RAS variants, BRAF codon 594 variants co-occur relatively frequently with RAS variants [21] . This study shows that successful participation in EQA, reflects complete and correct reporting of results for RAS testing in routine analysis. Despite the label given by EMA to EGFR-targeted agents for patients with mCRC, one laboratory did not test all relevant codons (12, 13, 59 , 61, 117, 146) and did not mention this limitation in the reports. This is an improvement compared to studies performed right after the labels changed [7, 12, 20] .
Because of the potential negative consequences following a false negative result, laboratories should be careful when reporting a wild-type sample in case of incomplete RAS testing. Also, laboratories using less sensitive methods, such as Sanger sequencing, without mentioning the sensitivity of the method in the report are at risk of reporting false negative results. The tested regions and limitations of the test should be clearly mentioned in the methods section of the patient report and further testing should be recommended for the complete RAS gene [22] . In addition, the tumor cell content is an important element on the report to allow an unambiguous interpretation of the result in relation to the used testing method [23] . Different elements were taken into account to provide a good estimation of the reproducibility of RAS testing. The selected group of participants had different experience levels with RAS testing and different settings. Laboratories following a specific standard and laboratories without accreditation were also included. The invited participants were good performers in EQA, which could lead to an overestimation of the general reproducibility of RAS testing in Europe. Taken this into account, it could be concluded that a good EQA performance is indicative of reliable performance in routine practice. Some EQA providers publish a list of laboratories that passed the EQA program [24, 25] .
Conclusion
The results show that patients and oncologists can rely on the results of routine RAS testing in pathology laboratories that successfully participated in EQA in Europe. Nevertheless, laboratories must acknowledge samples with limited quality in the diagnostic report. Providing conclusive results of such samples can result in a wrong therapy decision.
